UroGen Pharma to Present at the Jefferies 2018 Global Healthcare Conference

RA’ANANA, Israel and NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 at 11:00AM Eastern Time in New York, NY.

A live audio webcast of the event will be available on the Investors section of UroGen's website, www.urogen.com. A replay of the webcast will be available on the website for approximately two weeks following the live presentation.

About UroGen Pharma Ltd. UroGen Pharma Ltd. (Nasdaq: URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s lead product candidates, UGN-101 (MitoGel™) and UGN-102 (VesiGel™), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. UroGen is headquartered in Ra’anana, Israel with U.S. headquarters in New York.

UROGEN CONTACT:

Kate BechtoldDirector, Corporate Communications & Investor Relations[email protected] 914-552-0456

You May Also Be Interested In

• Jefferies Reiterates Buy Rating on UroGen Pharma (URGN)
• NWB Finland Oy Brings Retail-Friendly Sustainable Packaging to ECRM
• KBRA Assigns Preliminary Ratings to Sequoia Mortgage Trust 2026-HYB3 (SEMT 2026-HYB3)